Xin Wang, Xinran Wang, Steven D. Edland, Iris J. Broce, Anders M. Dale, Sarah J. Banks
Identifying low-cost, minimally-invasive screening instruments for Alzheimer's disease (AD) trial enrichment will improve the efficiency of AD trials.
为阿尔茨海默病（AD）试验浓缩确定低成本、微创的筛查工具将提高AD试验的效率。
{"title":"Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments","authors":"Xin Wang, Xinran Wang, Steven D. Edland, Iris J. Broce, Anders M. Dale, Sarah J. Banks","doi":"10.1002/alz.14284","DOIUrl":"https://doi.org/10.1002/alz.14284","url":null,"abstract":"Identifying low-cost, minimally-invasive screening instruments for Alzheimer's disease (AD) trial enrichment will improve the efficiency of AD trials.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"93 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Celine El Baou, Rob Saunders, Joshua E. J. Buckman, Marcus Richards, Claudia Cooper, Natalie L. Marchant, Roopal Desai, Georgia Bell, Caroline Fearn, Stephen Pilling, Nikki Zimmermann, Val Mansfield, Sebastian Crutch, Emilie Brotherhood, Amber John, Joshua Stott
People with dementia may benefit from psychological therapies for depression or anxiety, but evidence of their effectiveness in atypical dementia is limited.
痴呆症患者可能会从抑郁或焦虑的心理疗法中获益，但这些疗法对非典型痴呆症有效的证据却很有限。
{"title":"Effectiveness of psychological therapies for depression and anxiety in atypical dementia","authors":"Celine El Baou, Rob Saunders, Joshua E. J. Buckman, Marcus Richards, Claudia Cooper, Natalie L. Marchant, Roopal Desai, Georgia Bell, Caroline Fearn, Stephen Pilling, Nikki Zimmermann, Val Mansfield, Sebastian Crutch, Emilie Brotherhood, Amber John, Joshua Stott","doi":"10.1002/alz.14332","DOIUrl":"https://doi.org/10.1002/alz.14332","url":null,"abstract":"People with dementia may benefit from psychological therapies for depression or anxiety, but evidence of their effectiveness in atypical dementia is limited.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"13 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lindsay Master,Yuqi Shen,Alexa C Allan,May A Beydoun,Alan B Zonderman,Michele K Evans,Orfeu M Buxton,Alyssa A Gamaldo
INTRODUCTIONThis study evaluated the associations between Life's Essential 8 (LE8) and cognitive performance, and compared the strength of the relationships of Life's Simple 7 (LS7) and LE8 to cognition in midlife and older adults.METHODSParticipants (N = 1539) were from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study. Cross-sectional multivariable regression examined the associations between LE8 and cognition. Secondary analyses compared model performance between LE8 and LS7 measures on cognition from the same available sample.RESULTSHigher LE8 scores were associated with better global cognitive performance, working memory, and attention. The LS7 model outperformed the LE8 model on global cognitive performance, but the LE8 model outperformed the LS7 model for the working memory domain.DISCUSSIONBetter cardiovascular health (CVH) was associated with better cognitive performance among US middle-aged and older adults. However, the association between CVH and specific cognitive domains varies when using LE8 versus LS7.HIGHLIGHTSCardiovascular health (CVH) is associated with cognitive performance. Life's Essential 8 (LE8) is a new construct to quantify CVH. Associations between LE8 and cognition were assessed. Higher LE8 was associated with better global cognitive performance. Higher LE8 was also associated with better working memory and attention.
{"title":"Associations between AHA's Life's Essential 8 and cognition in midlife and older adults.","authors":"Lindsay Master,Yuqi Shen,Alexa C Allan,May A Beydoun,Alan B Zonderman,Michele K Evans,Orfeu M Buxton,Alyssa A Gamaldo","doi":"10.1002/alz.14294","DOIUrl":"https://doi.org/10.1002/alz.14294","url":null,"abstract":"INTRODUCTIONThis study evaluated the associations between Life's Essential 8 (LE8) and cognitive performance, and compared the strength of the relationships of Life's Simple 7 (LS7) and LE8 to cognition in midlife and older adults.METHODSParticipants (N = 1539) were from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study. Cross-sectional multivariable regression examined the associations between LE8 and cognition. Secondary analyses compared model performance between LE8 and LS7 measures on cognition from the same available sample.RESULTSHigher LE8 scores were associated with better global cognitive performance, working memory, and attention. The LS7 model outperformed the LE8 model on global cognitive performance, but the LE8 model outperformed the LS7 model for the working memory domain.DISCUSSIONBetter cardiovascular health (CVH) was associated with better cognitive performance among US middle-aged and older adults. However, the association between CVH and specific cognitive domains varies when using LE8 versus LS7.HIGHLIGHTSCardiovascular health (CVH) is associated with cognitive performance. Life's Essential 8 (LE8) is a new construct to quantify CVH. Associations between LE8 and cognition were assessed. Higher LE8 was associated with better global cognitive performance. Higher LE8 was also associated with better working memory and attention.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"235 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142489733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mónica Rivera Mindt,Alyssa Arentoft,Amanda T Calcetas,Vanessa A Guzman,Hannatu Amaza,Adeyinka Ajayi,Miriam T Ashford,Omobolanle Ayo,Lisa L Barnes,Alicia Camuy,Catherine Conti,Adam Diaz,Bashir Easter,David J Gonzalez,Yolanda Graham Dotson,Isabella Hoang,Kaori Kubo Germano,Gladys E Maestre,Fabiola Magaña,Oanh L Meyer,Melanie J Miller,Rachel Nosheny,Van M Ta Park,Shaniya Parkins,Lisa Renier Thomas,Joe Strong,Sandra Talavera,Steven P Verney,Trinity Weisensel,Michael W Weiner,Ozioma C Okonkwo,
INTRODUCTIONThe Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core was launched to advance Alzheimer's disease (AD) and AD-related dementia (ADRD) health equity research in underrepresented populations (URPs). We describe our evidence-based, scalable culturally informed, community-engaged research (CI-CER) model and demonstrate its preliminary success in increasing URP enrollment.METHODSURPs include ethnoculturally minoritized, lower education (≤ 12 years), and rural populations. The CI-CER model includes: (1) culturally informed methodology (e.g., less restrictive inclusion/exclusion criteria, sociocultural measures, financial compensation, results disclosure, Spanish Language Capacity Workgroup) and (2) inclusive engagement methods (e.g., the Engagement Core team; Hub Sites; Community-Science Partnership Board).RESULTSAs of April 2024, 60% of ADNI-4 new in-clinic enrollees were from ethnoculturally or educationally URPs. This exceeds ADNI-4's ≥ 50% URP representation goal for new enrollees but may not represent final enrollment.DISCUSSIONFindings show a CI-CER model increases URP enrollment in AD/ADRD clinical research and has important implications for clinical trials to advance health equity.HIGHLIGHTSThe Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) uses a culturally informed, community-engaged research (CI-CER) approach. The CI-CER approach is scalable and sustainable for broad, multisite implementation. ADNI-4 is currently exceeding its inclusion goals for underrepresented populations.
{"title":"The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed, community-engaged research (CI-CER) model to advance brain health equity.","authors":"Mónica Rivera Mindt,Alyssa Arentoft,Amanda T Calcetas,Vanessa A Guzman,Hannatu Amaza,Adeyinka Ajayi,Miriam T Ashford,Omobolanle Ayo,Lisa L Barnes,Alicia Camuy,Catherine Conti,Adam Diaz,Bashir Easter,David J Gonzalez,Yolanda Graham Dotson,Isabella Hoang,Kaori Kubo Germano,Gladys E Maestre,Fabiola Magaña,Oanh L Meyer,Melanie J Miller,Rachel Nosheny,Van M Ta Park,Shaniya Parkins,Lisa Renier Thomas,Joe Strong,Sandra Talavera,Steven P Verney,Trinity Weisensel,Michael W Weiner,Ozioma C Okonkwo,","doi":"10.1002/alz.14242","DOIUrl":"https://doi.org/10.1002/alz.14242","url":null,"abstract":"INTRODUCTIONThe Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core was launched to advance Alzheimer's disease (AD) and AD-related dementia (ADRD) health equity research in underrepresented populations (URPs). We describe our evidence-based, scalable culturally informed, community-engaged research (CI-CER) model and demonstrate its preliminary success in increasing URP enrollment.METHODSURPs include ethnoculturally minoritized, lower education (≤ 12 years), and rural populations. The CI-CER model includes: (1) culturally informed methodology (e.g., less restrictive inclusion/exclusion criteria, sociocultural measures, financial compensation, results disclosure, Spanish Language Capacity Workgroup) and (2) inclusive engagement methods (e.g., the Engagement Core team; Hub Sites; Community-Science Partnership Board).RESULTSAs of April 2024, 60% of ADNI-4 new in-clinic enrollees were from ethnoculturally or educationally URPs. This exceeds ADNI-4's ≥ 50% URP representation goal for new enrollees but may not represent final enrollment.DISCUSSIONFindings show a CI-CER model increases URP enrollment in AD/ADRD clinical research and has important implications for clinical trials to advance health equity.HIGHLIGHTSThe Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) uses a culturally informed, community-engaged research (CI-CER) approach. The CI-CER approach is scalable and sustainable for broad, multisite implementation. ADNI-4 is currently exceeding its inclusion goals for underrepresented populations.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"8 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lyuan Xu, Yu Zhao, Soyoung Choi, Muwei Li, Kurt G. Schilling, Zhongliang Zu, Baxter P. Rogers, Zhaohua Ding, Adam W. Anderson, Bennett A. Landman, John C. Gore, Yurui Gao
The magnitudes and patterns of alterations of the white–gray matter (WM–GM) functional connectome in preclinical Alzheimer's disease (AD), and their associations with amyloid and cognition, remain unclear.
{"title":"Reductions in the white–gray functional connectome in preclinical Alzheimer's disease and their associations with amyloid and cognition","authors":"Lyuan Xu, Yu Zhao, Soyoung Choi, Muwei Li, Kurt G. Schilling, Zhongliang Zu, Baxter P. Rogers, Zhaohua Ding, Adam W. Anderson, Bennett A. Landman, John C. Gore, Yurui Gao","doi":"10.1002/alz.14334","DOIUrl":"https://doi.org/10.1002/alz.14334","url":null,"abstract":"The magnitudes and patterns of alterations of the white–gray matter (WM–GM) functional connectome in preclinical Alzheimer's disease (AD), and their associations with amyloid and cognition, remain unclear.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"79 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexander P. Gabrielli, Lesya Novikova, Amol Ranjan, Xiaowan Wang, Nicholas J. Ernst, Dhanushki Abeykoon, Anysja Roberts, Annie Kopp, Clayton Mansel, Linlan Qiao, Colton R. Lysaker, Ian W. Wiedling, Heather M. Wilkins, Russell H. Swerdlow
Alzheimer's disease (AD) features changes in mitochondrial structure and function. Investigators debate where to position mitochondrial pathology within the chronology and context of other AD features.
{"title":"Inhibiting mtDNA transcript translation alters Alzheimer's disease-associated biology","authors":"Alexander P. Gabrielli, Lesya Novikova, Amol Ranjan, Xiaowan Wang, Nicholas J. Ernst, Dhanushki Abeykoon, Anysja Roberts, Annie Kopp, Clayton Mansel, Linlan Qiao, Colton R. Lysaker, Ian W. Wiedling, Heather M. Wilkins, Russell H. Swerdlow","doi":"10.1002/alz.14275","DOIUrl":"https://doi.org/10.1002/alz.14275","url":null,"abstract":"Alzheimer's disease (AD) features changes in mitochondrial structure and function. Investigators debate where to position mitochondrial pathology within the chronology and context of other AD features.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"56 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Richa Batra, Jan Krumsiek, Xue Wang, Mariet Allen, Colette Blach, Gabi Kastenmüller, Matthias Arnold, Nilüfer Ertekin-Taner, Rima Kaddurah-Daouk
Metabolic dysregulation is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). Although metabolic dysregulation is a common link between these two tauopathies, a comprehensive brain metabolic comparison of the diseases has not yet been performed.
{"title":"Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy","authors":"Richa Batra, Jan Krumsiek, Xue Wang, Mariet Allen, Colette Blach, Gabi Kastenmüller, Matthias Arnold, Nilüfer Ertekin-Taner, Rima Kaddurah-Daouk","doi":"10.1002/alz.14249","DOIUrl":"https://doi.org/10.1002/alz.14249","url":null,"abstract":"Metabolic dysregulation is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). Although metabolic dysregulation is a common link between these two tauopathies, a comprehensive brain metabolic comparison of the diseases has not yet been performed.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"125 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jonathan McLaughlin, William J. Scotton, Natalie S. Ryan, John A. Hardy, Maryam Shoai
Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.
{"title":"Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis","authors":"Jonathan McLaughlin, William J. Scotton, Natalie S. Ryan, John A. Hardy, Maryam Shoai","doi":"10.1002/alz.14314","DOIUrl":"https://doi.org/10.1002/alz.14314","url":null,"abstract":"Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"17 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rodolfo G. Gatto, Youssef Hossam, R. Ross Reichard, Val J. Lowe, Jennifer L. Whitwell, Keith A. Josephs
[18F] flortaucipir (FTP) binding to paired helical filament (PHF) tau in Alzheimer's disease (AD) is well accepted. Binding to 3R and 4R tau in frontotemporal lobar degeneration (FTLD) is controversial. We aimed to investigate whether an FTP fluorescent analog (T726) can help shed light on this controversy.
{"title":"Microscopy assessment of a fluorescence [18F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions","authors":"Rodolfo G. Gatto, Youssef Hossam, R. Ross Reichard, Val J. Lowe, Jennifer L. Whitwell, Keith A. Josephs","doi":"10.1002/alz.14330","DOIUrl":"https://doi.org/10.1002/alz.14330","url":null,"abstract":"[<sup>18</sup>F] flortaucipir (FTP) binding to paired helical filament (PHF) tau in Alzheimer's disease (AD) is well accepted. Binding to 3R and 4R tau in frontotemporal lobar degeneration (FTLD) is controversial. We aimed to investigate whether an FTP fluorescent analog (T726) can help shed light on this controversy.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"67 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer's Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer's disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to amyloid-positivity during their study participation to track evolution of biomarkers and cognitive function.
{"title":"Timing of Alzheimer's disease biomarker progressions: A two-decade observational study from the Alzheimer's Disease Neuroimaging Initiative (ADNI)","authors":"Tamar Schaap, Pamela Thropp, Duygu Tosun","doi":"10.1002/alz.14306","DOIUrl":"https://doi.org/10.1002/alz.14306","url":null,"abstract":"Alzheimer's Disease Neuroimaging Initiative (ADNI) has been pivotal in identifying and refining Alzheimer's disease (AD) biomarkers for clinical trials. This study leverages longitudinal data from participants who have progressed to amyloid-positivity during their study participation to track evolution of biomarkers and cognitive function.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"33 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：